Skip to Content

Marizyme Inc MRZM

Morningstar Rating
$0.09 −0.01 (6.92%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MRZM is trading within a range we consider fairly valued.
Price
$0.10
Fair Value
$7.39
Uncertainty
Extreme
1-Star Price
$7.22
5-Star Price
$5.46
Economic Moat
Vstv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRZM is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.10
Day Range
$0.090.09
52-Week Range
$0.050.41
Bid/Ask
$0.00 / $0.13
Market Cap
$4.13 Mil
Volume/Avg
3,000 / 6,530

Key Statistics

Price/Earnings (Normalized)
Price/Sales
6.38
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
13

Valuation

Metric
MRZM
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
6.38
Price/Cash Flow
Price/Earnings
MRZM

Financial Strength

Metric
MRZM
Quick Ratio
0.01
Current Ratio
0.03
Interest Coverage
−2.34
Quick Ratio
MRZM

Profitability

Metric
MRZM
Return on Assets (Normalized)
−93.97%
Return on Equity (Normalized)
−342.23%
Return on Invested Capital (Normalized)
−74.68%
Return on Assets
MRZM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHmzsnzvhqfCcx$571.0 Bil
VRTX
Vertex Pharmaceuticals IncNkbnkchcTkgrpz$107.8 Bil
REGN
Regeneron Pharmaceuticals IncWrfrdprqVtkmzt$106.1 Bil
MRNA
Moderna IncZdbpsflxPnbd$42.3 Bil
ARGX
argenx SE ADRRkzydlwhChwl$23.7 Bil
BNTX
BioNTech SE ADRSymyzbhHgdd$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncDrwzcsjtNkcpcsq$19.4 Bil
BMRN
Biomarin Pharmaceutical IncCfdvlkbmrBqvghh$16.7 Bil
RPRX
Royalty Pharma PLC Class APdzgtpcgbrMltxcx$13.6 Bil
INCY
Incyte CorpFxwylygzBtznb$12.8 Bil

Sponsor Center